Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

Hundreds of people with cystic fibrosis are to be offered a once-a-day pill which has been hailed as “life changing” by health experts.

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.